Microsoft Files With FTC Placing Argument Over Activision Blizzard Deal – $MSFT $DIA $INVO

By John F. Heerdink, Jr.

As per reports, Microsoft Corp (MSFT) filed an argument convincing a judge at the U.S. Federal Trade Commission to allow its bid to buy “Call of Duty” maker Activision Blizzard, after FTC commissioners said the merger would hamper competition in the gaming industry. However, the company put forward that its $69 billion bid to buy “Call of Duty” maker Activision Blizzard would benefit gamers and gaming companies alike.

In a complaint on December 8, the FTC raised concerns that Activision’s popular games, including “World of Warcraft” and “Diablo,” potentially would stop being offered on devices that are rival to Microsoft’s Xbox. The Microsoft deal is also facing scrutiny outside the United States, with the European Union saying it would decide by March 23, 2023, whether to allow or block the deal.

“The acquisition of a single game by the third-place console manufacturer cannot upend a highly competitive industry. That is particularly so when the manufacturer has made clear it will not withhold the game,” Microsoft stated in a filing.

Redmond, Washington-based American multinational technology company Microsoft (MSFT) develops, manufactures, licenses supports, and sells computer software, consumer electronics, personal computers, and related services. To learn more about Microsoft (MSFT) and to track their progress please visit the Vista Partners Coverage Page.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

DID YOU KNOW?

Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently.